HES5蛋白与肺腺癌患者病情及预后的相关性研究  

Correlation between HES5 protein and the condition and prognosis of patients with lung adenocarcinoma

作　　者：虞林湘[1] 章斌 施义[1] 薛建辉[1] 镇海文[1] 郁大江[1] 杨俊艺 YU Lin-xiang;ZHANG Bin;SHI Yi(Department of Cardiovascular Surgery,Jiangsu Provincial Hospital of Traditional Chinese Medicine,Nanjing Jiangsu 210029,China)

机构地区：[1]江苏省中医院心胸外科

出　　处：《临床和实验医学杂志》2020年第2期165-169,共5页Journal of Clinical and Experimental Medicine

基　　金：江苏省中医院资助项目(No.Y09035)

摘　　要：目的探究HES5蛋白表达水平与肺腺癌患者病情及预后相关性。方法回顾性收集江苏省中医院心胸外科离体后30 min内立即冻存于液氮中的4组肺腺癌组织和癌旁组织,采用Western Blot法分析HES5表达特征;收集2017年4月至2019年4月本院切除并经病理证实的48例肺腺癌标本(其中距肿瘤边缘>5 cm组织为癌旁正常组织),采用免疫组化染色法检测癌组织和癌旁组织HES5蛋白蛋白表达量,分析HES5蛋白表达量与性别、年龄、身体质量指数(BMI)、肿瘤直径、分化程度、肿瘤转移、肿瘤分期相关性;获取由手术时间起至患者死于癌症及癌症相关事件或纳入本研究36个月止的临床资料,根据患者生存情况分为生存组和死亡组,分析影响肺腺癌预后影响因素。结果HES5蛋白在分子量约为18 k Da处有显著表达,HES5蛋白在肺腺癌组织中表达升高,HES5蛋白在癌旁正常组织中表达降低,两者比较差异有统计学意义(P<0.05);肺腺癌组织中HES5阳性表达率高于癌旁组织中HES5阳性表达率(P<0.05)。TNM分期Ⅱ/Ⅲ期、有淋巴结转移、肿瘤直径>3 cm的肺腺癌患者HES5蛋白表达量高于分期I期、无淋巴结转移、肿瘤直径≤3 cm的肺腺癌患者HES5蛋白表达量(P<0.05)。3年随访期间存活患者28例(占比48.28%),死亡30例(占比51.72%);肿瘤直径>3 cm、分化程度为低/中分化、有淋巴结转移、TNM分期Ⅱ/Ⅲ期、HES5蛋白高表达的肺腺癌患者存活率低于肿瘤直径≤3 cm、分化程度为高分化、无淋巴结转移、TNM分期I期、HES5蛋白低表达的肺腺癌患者存活率(P<0.05)。COX多因素结果显示,HES5蛋白表达、TNM分期是影响肺腺癌患者预后独立影响因素(P<0.05)。结论HES5蛋白在肺腺癌肿瘤组织中呈高表达水平,可负向调控肺腺癌患者肿瘤分级、肿瘤分期、肿瘤转移及病情进展,检测HES5蛋白表达水平可为肺腺癌患者早期诊疗及预后评估提供参考依据。Objective To investigate the correlation between HES5 protein and the condition and prognosis of patients with lung adenocarcinoma.Methods Four groups of cancer tissues and adjacent tissues collected and frozen in liquid nitrogen within 30 minutes after cardiothoracic surgery in our hospital were enrolled.The expression characteristics of HES5 in those tissues were analyzed by Western Blot.The lung adenocarcinoma tissues and adjacent normal tissues collected from 48 cases of pathologically confirmed lung adenocarcinoma patients were selected.HES5 protein expression in cancer tissues and adjacent tissues was detected by immunohistochemical staining.The correlation between HES5 protein expression and gender,age,body mass index(BMI),tumor diameter,degree of differentiation,tumor metastasis and tumor stage was analyzed.The clinical data of 36 months were collected.Patients were divided into survival group and death group according to the prognosis of the patients.Results HES5 protein was significantly expressed at a molecular weight of approximately 18 k Da,HES5 protein was elevated in lung adenocarcinoma tissues,and decreased in adjacent normal tissues(P<0.05).The positive expression rate of HES5 in lung adenocarcinoma tissues was higher than that in adjacent tissues(P<0.05).The expression of HES5 protein in patients with lung adenocarcinoma with TNM stage II/III,lymph node metastasis and tumor diameter>3 cm was higher than that of stage I,non-lymph node metastasis,and tumor diameter≤3 cm(P<0.05).During the 3-year follow-up period,28 patients survived(48.28%)and 30 died(51.72%).The survival rate of lung adenocarcinoma patients with tumor diameter>3 cm,low/moderate differentiation,lymph node metastasis,TNM stage II/III,high HES5 protein expression was lower than that of lung adenocarcinoma patients with tumor diameter≤3 cm,high differentiation,non lymph node metastasis,TNM stage I,and low HES5 protein expression(P<0.05).COX multivariate results showed that HES5 protein expression and TNM staging were independent

关 键 词：肺腺癌 HES5蛋白 病情 预后 相关性 

分 类 号：R734.2[医药卫生—肿瘤]